Glaucoma, high eye pressure or ocular hypertension is a condition that can be devastating for our eyesight. Increased eye pressure can ruin the retina and even blindness. There are existing treatments against high eye pressure, but these are not always effective. Palmitoylethanolamide offers new and natural possibility to decrease pressure and protect the retina. Many patients already benefited from this substance. We will start with an example:
Mother has glaucoma and drop hurt the eye
My mother has glaucoma and the eye drops hurt tremendously as she has very dry eyes. She now takes 1 PEA capsule a day and within a month her eye pressure decreased to normal levels (she has seen an optician twice for measurements) and on top of that she only has to take 1 glaucoma drop per day, which really relaxed her eyes and decreased irritation.
Eye doctors are looking
Eye doctors have been looking for new treatments for years. Together with a professor in ophthalmology we brought together all studies concerning glaucoma and protection of the retina. The results are impressive.
For example, one of the randomized double-blinded studies showed that the natural palmitoylethanolamide can decrease eye pressure and on top of that is good for the blood vessels in the eye and protects the retina against further damage. It even has the potential to repair the damage, making it a natural substance with a possible 4 different effects against glaucoma. It is easily combined with other medicine. Oculists in Italy have been using this substance since 10 years with good results.
Meanwhile, oculists in the United States are also impressed and advise PEA as the first step in treating glaucoma. The organization Fiteyes and affiliated oculists in the US advise PEA for glaucoma. This organization is so excited about PEA that they made the picture as seen here.
Palmitoylethanolamide: good for eyes with increased eye pressure (glaucoma), a natural treatment
The goal of a recent (2013) study, which we will discuss here,  was to determine the value of PEA in the treatment of increased eye pressure and the value in protection of the vascular walls and blood vessels in the eye.
To assess the effect of Palmitoylethanolamide (PEA) on systemic endothelial function in ocular hypertensive patients (OH) (glaucoma).
The method was done entirely by the book, randomized and placebo controlled:
Randomized double-blind placebo-controlled crossover single-center study. Forty never treated OH patients and 40 healthy age-matched controls were enrolled. At baseline, each participant underwent endothelium dependent flow-mediated vasodilation (FMD) measurement using a non-invasive high-resolution 2-dimensional ultrasonographic imaging of the brachial artery. OH patients were randomly assigned to receive either 300 mg PEA (Group A) or a matching placebo (Group B), twice a day, for three months.
After three months of treatment, the results showed that the eye pressure decreased significantly and the function of the blood vessels improved, a double benefit:
Three-month PEA intake reduced IOP and led to significantly improved FMD values in OH patients compared to placebo, by ameliorating peripheral endothelial function and its positive effect lasted longer than the period of PEA consumption. No adverse events were recorded
There were no side effects.
There are other ophthalmologic studies that have been published showing the positive effect of PEA on glaucoma, also after a six-month usage.    Recently it turned out that one of the effects that PEA has on glaucoma is that it actively removes access liquid from the eye. 
PEA protects nerve cells against damage
This turns out to be an important advantage of PEA. PEA is a special substance, which pharmacologists and physiologists refer to as an autacoid. Autacoids are substances produced by the body and have a healing and protective effect towards damage to the body. It’s a way of ‘self-treatment’. This is why it’s said that PEA is one of the pillars of the self-healing ability of the body. Below you can see the 4 main qualities of PEA when it comes to glaucoma or other conditions that threaten the retina.
PEA protects the retina and decreases eye pressure in glaucoma
PEA has no less than 4 different working mechanisms:
- Decreases eye pressure
- It inhibits the chronic inflammation of the retina (which may arise due to glaucoma)
- It protects the retina cells against damage
- It repairs the damaged cells. Certain eye infections also respond positively to treatment with PEA. 
It has been known for a while that PEA can protect cells that are threatened by increased pressure of oxygen shortage.  This is called a neuroprotective effect.  This is extremely important for glaucoma, because the increased eye pressure damage the cells in of the retina. Once damaged, the cells can’t contribute to vision anymore, creating blind spots or so-called loss of vision. So PEA doesn’t only decrease pressure, but also protects the veins and nerves of the eye against damage.
Pure PEA against glaucoma
PEA is available in the United States as a supplement (PeaCure) that only contains pure PEA.
The dose for treating increased eye pressure (glaucoma) based on our experience is 1-2 capsules (of 400mg each) twice a day, so the total daily dose comes to 800 or preferably 1200mg.
Meanwhile, PEA has been proven safe for thousands of patients, with no reported side effects, and its effectiveness has been showed through different studies. Because of this reason, PEA gets a green light.
PEA can be safely combined with any other ophthalmology treatment. You can inform your doctor about PEA through the summary under this link.
 Strobbe E, Cellini M, Campos EC. | Effectiveness of palmitoylethanolamide on endothelial dysfunction in ocular hypertensive patients: a randomized, placebo-controlled cross-over study. |Invest Ophthalmol Vis Sci. | 2013 Feb 1;54(2):968-73. doi: 10.1167/iovs.12-10899.
 Pescosolido N, Puzzono M. | First clinical case of effective medical treatment of the vitreoretinal traction with recovery of the visual acuity. | Clin Ter. | 2010;161(4):e143-7.
 Pescosolido N, Librando A, Puzzono M, Nebbioso M. | Palmitoylethanolamide effects on intraocular pressure after Nd:YAG laser iridotomy: an experimental clinical study. | J Ocul Pharmacol Ther. | 2011 Dec;27(6):629-35. doi: 10.1089/jop.2010.0191. Epub 2011 Aug 10.
 Gagliano C, Ortisi E, Pulvirenti L, Reibaldi M, Scollo D, Amato R, Avitabile T, Longo A. |Ocular hypotensive effect of oral palmitoyl-ethanolamide: a clinical trial. | Invest Ophthalmol Vis Sci. | 2011 Aug 3;52(9):6096-100. doi: 10.1167/iovs.10-7057.
 Kumar A, Qiao Z, Kumar P, Song ZH. | Effects of palmitoylethanolamide on aqueous humor outflow. | Invest Ophthalmol Vis Sci. | 2012 Jul 3;53(8):4416-25. doi: 10.1167/iovs.11-9294.
 Impellizzeri D1, Ahmad A1, Bruschetta G1, Di Paola R1, Crupi R1, Paterniti I1, Esposito E1, Cuzzocrea S2. | The anti-inflammatory effects of palmitoylethanolamide (PEA) on endotoxin-induced uveitis in rats. | Eur J Pharmacol. | 2015 Aug 15;761:28-35. doi: 10.1016/j.ejphar.2015.04.025. Epub 2015 Apr 28.
 Paterniti I1, Impellizzeri D, Crupi R, Morabito R, Campolo M, Esposito E, Cuzzocrea S. |Molecular evidence for the involvement of PPAR-? and PPAR-? in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma. | J Neuroinflammation. | 2013 Feb 1;10:20. doi: 10.1186/1742-2094-10-20.
 Scuderi C1, Stecca C1, Valenza M2, Ratano P1, Bronzuoli MR1, Bartoli S1, Steardo L3, Pompili E4, Fumagalli L4, Campolongo P1, Steardo L1. | Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer’s disease. | Cell Death Dis. | 2014 Sep 11;5:e1419. doi: 10.1038/cddis.2014.376.